Form 4: Boston Scientific EVP Sells Shares Under 10b5-1 Plan

Sentiment:

Insider Transaction Report 2 December 2025 5:04 PM

Boston Scientific's EVP Arthur C. Butcher sold 17,313 shares of common stock for over $101 per share after exercising options, all under a pre-established 10b5-1 trading plan.

Summary

Arthur C. Butcher, EVP & Group President, MedSurg & APAC at Boston Scientific Corp (BSX), executed transactions on December 1, 2025.
These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
Butcher exercised stock options to acquire a total of 17,313 shares of common stock at exercise prices ranging from $17.26 to $27.09 per share.
Concurrently, he sold 17,313 shares of common stock at a weighted average price of $101.5531 per share, with individual sales ranging from $101.11 to $101.89.
Following these transactions, Butcher directly owns 23,600 shares and indirectly owns 13,354 shares through a 401(k) plan, totaling 36,954 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the fact that it was executed under a pre-established 10b5-1 plan mitigates concerns about opportunistic selling. The executive also retains a significant stake in the company, and the high sale price relative to exercise price indicates a successful compensation event.

Positives

The transactions were executed under a pre-established Rule 10b5-1 trading plan, indicating a planned, non-opportunistic sale.
The sale price of over $101 per share is significantly higher than the option exercise prices, indicating a substantial profit for the executive.
The executive retains a significant number of shares (36,954 total) after the sale, maintaining alignment with shareholder interests.

Negatives

Insider selling, even if pre-planned, can sometimes be perceived negatively by the market as it reduces an executive's direct equity stake.

Future Outlook

Industry Context

This transaction is a routine insider filing for an executive at a major medical technology company. It reflects personal financial planning rather than a direct commentary on Boston Scientific's operational performance or broader industry trends. The medical device industry often sees executives managing their equity compensation through pre-planned sales.

Comparison to Industry Standards

The execution of stock option exercises and subsequent sales under a Rule 10b5-1 plan is a standard practice for executives in publicly traded companies across all industries, including medical technology. This allows insiders to diversify their holdings and manage liquidity while adhering to insider trading regulations. There are no specific comparable companies or projects mentioned in this filing to assess against.

Stakeholder Impact

Shareholders: The sale by an executive could be perceived as a slight negative, but the 10b5-1 plan context and retained holdings mitigate this. The transaction itself does not directly impact company operations or financial performance.
Employees: No direct impact on employees.
Customers: No direct impact on customers.
Suppliers: No direct impact on suppliers.
Creditors: No direct impact on creditors.

Key Dates

Date	Description
February 22, 2017	First anniversary of grant date for options with $17.26 exercise price, vesting in four equal annual installments.
June 1, 2017	First anniversary of grant date for options with $22.71 exercise price, vesting in four equal annual installments.
February 28, 2018	First anniversary of grant date for options with $24.55 exercise price, vesting in four equal annual installments.
February 15, 2019	First anniversary of grant date for options with $27.09 exercise price, vesting in four equal annual installments.
August 9, 2024	Date the Rule 10b5-1 trading plan was adopted.
December 1, 2025	Date of the reported option exercise and stock sale transactions.
February 22, 2026	Expiration date for options with $17.26 exercise price.
June 1, 2026	Expiration date for options with $22.71 exercise price.
February 28, 2027	Expiration date for options with $24.55 exercise price.
February 15, 2028	Expiration date for options with $27.09 exercise price.
December 2, 2025	Signature date of the Form 4 filing.

Recommendation

hold

This Form 4 filing details a routine, pre-planned insider transaction by an executive exercising stock options and selling shares. The execution under a Rule 10b5-1 plan suggests personal financial planning rather than a signal about the company's future performance. While insider selling can sometimes be a bearish signal, the context here makes it a neutral event. The executive retains a substantial equity stake. Therefore, this filing alone does not provide sufficient new information to warrant a change in investment thesis for Boston Scientific, leading to a 'hold' recommendation based solely on this report.

Keywords

Boston Scientific, BSX, Arthur C. Butcher, Insider Trading, Form 4, Stock Options, Equity Sales, 10b5-1 Plan, Executive Compensation, Medical Devices

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.